Investigational Medication for people with Relapsing Remitting Multiple Sclerosis

3-month study evaluating the efficacy and safety of ofatumumab, given as an injection under the skin once a month. After completion of the three month study, patients will be given the opportunity to receive ofatumumab at no cost for 4.5 years through an extension trial. There is no use of a placebo in either of these trials.

  • Ages 18-55
  • Subjects must have at least one relapse in the past year or two over the past two years

For more information please contact Deb@alpineresearch.com or call 303-443-7229

 

Share